Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Duvax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Duvax: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ceforanide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Ceforanide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IOV-5001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
IOV-5001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RBN-3143 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
RBN-3143: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Autologous hALK.CAR T cells(The Children's Hospital Corp) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Autologous hALK.CAR T cells(The Children's Hospital Corp): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
RO-7446603 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
RO-7446603: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IG-3018 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
IG-3018: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ACIT-1 cancer vaccine(Cancer Vaccines Limited) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
ACIT-1 cancer vaccine(Cancer Vaccines Limited): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
DAW-2020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
DAW-2020: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
KLS-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
KLS-1: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EN-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
EN-002: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Induced-T cell Like NK cells(Hunan Zhaotai Yongren Medical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Induced-T cell Like NK cells(Hunan Zhaotai Yongren Medical): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.